Retatrutide activates GLP-1, GIP and glucagon receptors. In the 2026 TRIUMPH-1 trial, 2,339 adults with obesity without diabetes were randomized to retatrutide or placebo. At 80 weeks, the highest study group averaged 25.0% weight loss versus 3.9% with placebo under the treatment-regimen analysis, which accounts for treatment discontinuation. These are clinical-preparation findings, not proof of equivalent research-vial effects.

TRIUMPH-1 also examined participants with knee osteoarthritis and participants with obstructive sleep apnea. Retatrutide reduced measured knee pain and breathing-interruption rates compared with placebo in those subgroups. These findings describe symptom and breathing outcomes in selected adults with obesity. They do not demonstrate cartilage regeneration, apply to every cause of knee pain, or justify stopping prescribed sleep-apnea care.

Retatrutide, tirzepatide, semaglutide and cagrilintide act through different hormone pathways. Their trials also differ in participants, duration and statistical methods. A larger percentage from a separate study cannot establish which compound works best. Comparisons are most informative when they measure the same outcome in participants assigned within the same trial.

Early human research estimated a retatrutide half-life of approximately six days, meaning the blood concentration falls by about half over that period. This helps explain its development as a long-acting medicine, but does not establish a personal schedule. Clinical trials reported digestive adverse effects and changes in heart rate, so weight-loss findings need to be read alongside tolerability.